225 related articles for article (PubMed ID: 25415047)
1. Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: analysis of 1806 cases.
Gatalica Z; Millis SZ; Vranic S; Bender R; Basu GD; Voss A; Von Hoff DD
Oncotarget; 2014 Dec; 5(23):12440-7. PubMed ID: 25415047
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy.
Gatalica Z; Xiu J; Swensen J; Vranic S
Eur J Cancer; 2018 May; 94():179-186. PubMed ID: 29571084
[TBL] [Abstract][Full Text] [Related]
3. A Review on Cancer of Unknown Primary Origin: The Role of Molecular Biomarkers in the Identification of Unknown Primary Origin.
Yan N; Zhang Y; Guo X; Yuan D; Tian G; Yang J
Methods Mol Biol; 2020; 2204():109-119. PubMed ID: 32710319
[TBL] [Abstract][Full Text] [Related]
4. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation.
Varadhachary GR; Talantov D; Raber MN; Meng C; Hess KR; Jatkoe T; Lenzi R; Spigel DR; Wang Y; Greco FA; Abbruzzese JL; Hainsworth JD
J Clin Oncol; 2008 Sep; 26(27):4442-8. PubMed ID: 18802157
[TBL] [Abstract][Full Text] [Related]
5. Molecular profiling for CUP cancers: are we there yet?
Varadhachary G
Onkologie; 2012; 35(1-2):11-2. PubMed ID: 22310338
[No Abstract] [Full Text] [Related]
6. Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary.
Tothill RW; Li J; Mileshkin L; Doig K; Siganakis T; Cowin P; Fellowes A; Semple T; Fox S; Byron K; Kowalczyk A; Thomas D; Schofield P; Bowtell DD
J Pathol; 2013 Dec; 231(4):413-23. PubMed ID: 24037760
[TBL] [Abstract][Full Text] [Related]
7. RNA-Seq accurately identifies cancer biomarker signatures to distinguish tissue of origin.
Wei IH; Shi Y; Jiang H; Kumar-Sinha C; Chinnaiyan AM
Neoplasia; 2014 Nov; 16(11):918-27. PubMed ID: 25425966
[TBL] [Abstract][Full Text] [Related]
8. Multiplatform molecular profiling identifies potentially targetable biomarkers in malignant phyllodes tumors of the breast.
Gatalica Z; Vranic S; Ghazalpour A; Xiu J; Ocal IT; McGill J; Bender RP; Discianno E; Schlum A; Sanati S; Palazzo J; Reddy S; Pockaj B
Oncotarget; 2016 Jan; 7(2):1707-16. PubMed ID: 26625196
[TBL] [Abstract][Full Text] [Related]
9. Genomic Profiling of Cancers of Unknown Primary Site--Reply.
Ross JS; Miller VA; Stephens PJ
JAMA Oncol; 2015 Jul; 1(4):542-3. PubMed ID: 26181269
[No Abstract] [Full Text] [Related]
10. Genomic Profiling of Cancers of Unknown Primary Site: The Next Steps.
Cobain EF; Chinnaiyan AM; Kurzrock R; Baker LH
JAMA Oncol; 2015 Jul; 1(4):542. PubMed ID: 26181268
[No Abstract] [Full Text] [Related]
11. Genomic Profiling of Cancers of Unknown Primary Site: The Next Steps.
Varghese AM; Saltz LB
JAMA Oncol; 2015 Jul; 1(4):541-2. PubMed ID: 26181267
[No Abstract] [Full Text] [Related]
12. Genomic Profiling of Cancers of Unknown Primary Site: The Next Steps.
Whang YE; Hayes DN
JAMA Oncol; 2015 Jul; 1(4):541. PubMed ID: 26181266
[No Abstract] [Full Text] [Related]
13. Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay.
Greco FA; Lennington WJ; Spigel DR; Hainsworth JD
Mol Diagn Ther; 2015 Apr; 19(2):91-7. PubMed ID: 25758902
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options.
Ang C; Miura JT; Gamblin TC; He R; Xiu J; Millis SZ; Gatalica Z; Reddy SK; Yee NS; Abou-Alfa GK
J Surg Oncol; 2016 Jan; 113(1):55-61. PubMed ID: 26661118
[TBL] [Abstract][Full Text] [Related]
15. Carcinoma of Unknown Primary Site: The Poster Child for Personalized Medicine?
Varadhachary G
JAMA Oncol; 2015 Apr; 1(1):19-21. PubMed ID: 26182299
[No Abstract] [Full Text] [Related]
16. The role of molecular profiling in the diagnosis and management of metastatic undifferentiated cancer of unknown primary
Dermawan JK; Rubin BP
Semin Diagn Pathol; 2021 Nov; 38(6):193-198. PubMed ID: 33309276
[TBL] [Abstract][Full Text] [Related]
17. New strategies for carcinoma of unknown primary: the role of tissue-of-origin molecular profiling.
Varadhachary G
Clin Cancer Res; 2013 Aug; 19(15):4027-33. PubMed ID: 23519898
[TBL] [Abstract][Full Text] [Related]
18. Identification of tissue of origin in carcinoma of unknown primary with a microarray-based gene expression test.
Monzon FA; Medeiros F; Lyons-Weiler M; Henner WD
Diagn Pathol; 2010 Jan; 5():3. PubMed ID: 20205775
[TBL] [Abstract][Full Text] [Related]
19. Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology.
Greco FA; Lennington WJ; Spigel DR; Hainsworth JD
J Natl Cancer Inst; 2013 Jun; 105(11):782-90. PubMed ID: 23641043
[TBL] [Abstract][Full Text] [Related]
20. Integrating a 92-Gene Expression Analysis for the Management of Neuroendocrine Tumors of Unknown Primary.
Chauhan A; Farooqui Z; Silva SR; Murray A; Hodges KB; Yu Q; Myint ZW; Raajesekar AK; Weiss H; Arnold S; Evers BM; Anthony L
Asian Pac J Cancer Prev; 2019 Jan; 20(1):113-116. PubMed ID: 30678389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]